Medroxyprogesterone Acetate
Generic Name: medroxyprogesterone acetate
Brand Names:
Medroxyprogesterone Acetate
Medroxyprogesterone acetate is a contraceptive injectable suspension available as a sterile aqueous suspension of 150 mg/mL, indicated for use by females of reproductive potential to prevent pregnancy.
Overview
Medroxyprogesterone acetate is a contraceptive injectable suspension available as a sterile aqueous suspension of 150 mg/mL, indicated for use by females of reproductive potential to prevent pregnancy.
Uses
Indicated for use by females of reproductive potential to prevent pregnancy. Not recommended as long-term (>2 years) birth control unless other options are inadequate.
Dosage
150 mg via deep intramuscular injection every 3 months (13 weeks) in gluteal or deltoid muscle. First injection during first 5 days of menstrual period or within 5 days postpartum.
Side Effects
Common: menstrual irregularities (57% at 12 months), weight gain >10 lb (38% at 24 months), headache (16.5%), abdominal pain (11.2%), nervousness (10.8%).
Interactions
Enzyme inducers (barbiturates, carbamazepine, rifampin, St. John's wort) may decrease effectiveness. HIV protease inhibitors and antibiotics may affect progestin levels.
Warnings
Black box warning: Women who use MPA may lose significant bone mineral density. Bone loss greater with longer use, may not be completely reversible. Not recommended as long-term birth control (>2 years) unless other options inadequate. Risks include thromboembolic disorders, cancer, meningioma, ectopic pregnancy, anaphylaxis, liver function disturbances.
Pregnancy
No use in pregnancy; should discontinue if pregnancy occurs. No increased birth defect risk from prior exposure based on epidemiologic studies. Detectable in breast milk but appears safe. For exclusive breastfeeding, initiate at 6+ weeks postpartum.
Frequently Asked Questions
What is Medroxyprogesterone Acetate used for?▼
Indicated for use by females of reproductive potential to prevent pregnancy. Not recommended as long-term (>2 years) birth control unless other options are inadequate.
What are the side effects of Medroxyprogesterone Acetate?▼
Common: menstrual irregularities (57% at 12 months), weight gain >10 lb (38% at 24 months), headache (16.5%), abdominal pain (11.2%), nervousness (10.8%).
Can I take Medroxyprogesterone Acetate during pregnancy?▼
No use in pregnancy; should discontinue if pregnancy occurs. No increased birth defect risk from prior exposure based on epidemiologic studies. Detectable in breast milk but appears safe. For exclusive breastfeeding, initiate at 6+ weeks postpartum.
What are the important warnings for Medroxyprogesterone Acetate?▼
Black box warning: Women who use MPA may lose significant bone mineral density. Bone loss greater with longer use, may not be completely reversible. Not recommended as long-term birth control (>2 years) unless other options inadequate. Risks include thromboembolic disorders, cancer, meningioma, ectopic pregnancy, anaphylaxis, liver function disturbances.
Related Medications
Allenrolfea Occidentalis
allenrolfea occidentalis
Dosage form: SOLUTION. Route: INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS. Active ingredients: ALLENROLFEA OCCIDENTALIS POLLEN (.05 g/mL). Category: BLA.
Fulvestrant
fulvestrant
Estrogen Receptor Antagonist [EPC]
Fulvestrant is an estrogen receptor antagonist indicated for hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women, available as monotherapy or in combination with CDK4/6 inhibitors.
Zinc Oxide 24%
zinc oxide 24%
Sunscreen
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.